Mangoceuticals, Inc.: Form 10-Q/A for the period ended Jun 30, 2025
Filed with the SEC on Nov 14, 2025 and accepted by EDGAR at Nov 14, 2025, 16:37 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $168.1k | us-gaap:Revenues |
| Revenue | 6 months2025-01-01 to 2025-06-30 | $277.4k | us-gaap:Revenues |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $18.8k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2025-01-01 to 2025-06-30 | $43.6k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2025-04-01 to 2025-06-30 | $89.9k | us-gaap:GrossProfit |
| Gross profit | 6 months2025-01-01 to 2025-06-30 | $152.0k | us-gaap:GrossProfit |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$5.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2025-01-01 to 2025-06-30 | −$10.1m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-04-01 to 2025-06-30 | $21.7k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2025-01-01 to 2025-06-30 | $8.0k | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2025-04-01 to 2025-06-30 | −$5.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2025-01-01 to 2025-06-30 | −$10.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | −$0.57 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2025-01-01 to 2025-06-30 | −$1.60 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | −$0.57 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2025-01-01 to 2025-06-30 | −$1.60 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 9,983,376 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2025-01-01 to 2025-06-30 | 7,282,955 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2025-01-01 to 2025-06-30 | −$3.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-06-30 | $101.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $118.0k | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $20.8m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $1.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $1.6m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $19.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-25-023566. Last ingested by Listed: Nov 6, 2026, 18:28 ET. Listed shows no prices and gives no investment advice.